Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

88652d2f-b913-41e8-bd7c-c40967e94d5f

—

194b4cbd-0a3e-50d8-bf89-a7d347e639e1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • ANGIOGENESIS+0.400
  • COAGULATION+0.400
  • COMPLEMENT+0.400
  • IL2_STAT5_SIGNALING+0.400
  • IL6_JAK_STAT3_SIGNALING+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • KRAS_SIGNALING_UP+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.400

Top 10 suppressed

  • MITOTIC_SPINDLE-0.400
  • HEDGEHOG_SIGNALING-0.200
  • UV_RESPONSE_DN-0.200
  • WNT_BETA_CATENIN_SIGNALING-0.200
  • DNA_REPAIR-0.100
  • MYC_TARGETS_V2-0.100
  • P53_PATHWAY-0.100
  • PI3K_AKT_MTOR_SIGNALING-0.100
  • PROTEIN_SECRETION-0.100
  • UNFOLDED_PROTEIN_RESPONSE-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-2131
medullo-epn-umap@date-based
MedMedulloblastoma0.857
2GSM6454748
breast-umap@18
—C0.857
3SRR1313163
breast-umap@18
—D0.856
4MDT-AP-0410
medullo-epn-umap@date-based
MedMedulloblastoma0.853
5TCGA-64-1676-01A-01R-0946-07
lung-landscapes@6
—cohortA10.851
6TCGA-35-4122-01A-01R-1107-07
lung-landscapes@6
—cohortA10.851
7TCGA-C8-A26X-01A-31R-A16F-07
breast-umap@18
—C0.850
8SRR33532823
breast-umap@18
—C0.848
9TCGA-D8-A1Y2-01A-11R-A157-07
breast-umap@18
—C0.847
10MDT-AP-0499
medullo-epn-umap@date-based
MedMedulloblastoma0.846

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
COAGULATION0.400Binimetinib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.300Inavolisib— uncovered
FATTY_ACID_METABOLISM0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
APOPTOSIS0.200Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.200Inavolisib— uncovered